Rasalam, Roy, Rudofsky, Gottfried, Bodholdt, Ulrik, Catarig, Andrea-Mircea, Ekberg, Neda, Erhan, Umut, Liutkus, Joanne, Tariq, Mohd, and Holmes, Patrick (2022) Patients reaching treatment targets with once-weekly semaglutide in real‑world practice: pooled analysis of four SURE studies. In: [Presented at the Australasian Diabetes Congress 2022]. From: Australasian Diabetes Congress 2022, 8-10 August 2022, Brisbane, QLD, Australia.

Preview

PDF - Published Version Download (215kB) | Preview

Abstract

Once weekly (OW) subcutaneous (s.c.) semaglutide is a glucagon‑like peptide-1 receptor agonist (GLP-1RA) approved for type 2 diabetes (T2D) treatment. Real-world evidence studies are important to understand the use of a drug in routine clinical practice and in diverse patient populations. This pooled post hoc analysis of four SURE studies (N=1,212) evaluated patients achieving HbA1c and weight-loss targets.These results from a real-world setting in five countries support the use of OW semaglutide in routine clinical practice in a broad range of adults with T2D.

Item ID:	76939
Item Type:	Conference Item (Poster)
Keywords:	type 2 diabetes; semaglutide; GLP1-RA
Date Deposited:	05 Dec 2022 23:22
FoR Codes:	32 BIOMEDICAL AND CLINICAL SCIENCES > 3202 Clinical sciences > 320208 Endocrinology @ 70% 42 HEALTH SCIENCES > 4203 Health services and systems > 420304 General practice @ 30%
SEO Codes:	28 EXPANDING KNOWLEDGE > 2801 Expanding knowledge > 280103 Expanding knowledge in the biomedical and clinical sciences @ 20% 20 HEALTH > 2001 Clinical health > 200105 Treatment of human diseases and conditions @ 40% 20 HEALTH > 2001 Clinical health > 200102 Efficacy of medications @ 40%
Downloads:	Total: 80 Last 12 Months: 5
	More Statistics